Impact of Propranolol Strategies on Myocardial Injury After Breast Cancer Surgery (NCT07583134) | Clinical Trial Compass
Not Yet RecruitingPhase 4
Impact of Propranolol Strategies on Myocardial Injury After Breast Cancer Surgery
South Korea100 participantsStarted 2026-05-26
Plain-language summary
This study aims to evaluate the impact of using propranolol, a non-selective beta-blocker, on preventing myocardial injury after non-cardiac surgery (MINS) in breast cancer patients who also have hypertension or angina. Stress from surgery and anesthesia can increase sympathetic activity and inflammation, which may lead to heart stress. This pragmatic clinical trial will compare patients who are prescribed propranolol as part of their routine care with those who are not. Researchers will analyze blood samples and surgical tissues collected during normal treatment to observe changes in heart health and the tumor microenvironment.
Who can participate
Age range
20 Years – 70 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Female patients aged 20 to 70 years.
. Patients diagnosed with hypertension or angina who require medication.
. Patients diagnosed with unilateral, resectable primary breast cancer (ICD-10: C50), Stage I-III.
. ECOG performance status of 0-1.
. Patients scheduled to receive standard postoperative treatment (including adjuvant radiotherapy
. Patients who voluntarily decide to participate and sign the written informed consent form
Exclusion criteria
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial is specifically looking at whether propranolol — a beta-blocker — can reduce heart muscle injury after breast cancer surgery, so could you explain whether my own heart health history makes this kind of injury a real risk for me personally?
2Since this trial is Phase 4, meaning propranolol is already an approved medication, does that change what we know about its safety compared to earlier-phase trials, and are there any risks specific to using it around surgery that I should understand?
3The trial is listed as 'not yet recruiting' — how long might it realistically be before it opens and accepts patients, and would waiting to potentially join it affect the timing of my breast cancer treatment?
4Myocardial injury after noncardiac surgery (MINS) can sometimes have no obvious symptoms, so if I don't end up in this trial, is there a way my care team would monitor or test for this kind of heart injury after my surgery anyway?
5Are there standard-of-care approaches my surgical team already uses to protect my heart during breast cancer surgery, and how would joining this propranolol trial compare to or overlap with those existing precautions?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Incidence of Myocardial Injury after Noncardiac Surgery (MINS)
Timeframe: From the day of surgery (Day 0) up to 30 days postoperatively
. Patients with active infectious diseases, autoimmune diseases (including specific rheumatic diseases), coagulation disorders, or cardiovascular diseases other than hypertension or angina pectoris.
. Patients with clinically significant hepatic, hematologic, or renal dysfunction, defined as any of the following:
. Patients with moderate to severe asthma or chronic obstructive pulmonary disease (COPD).
. Patients who are pregnant or breastfeeding at the time of enrollment.
. Patients with a history of malignancy within the past 5 years.
. Patients for whom data collection is considered difficult at the discretion of the investigator.
. Patients who are unable to understand or complete study questionnaires.